CONFIDENTIAL PROVISIONS MARKED AMENDMENT NO. 2 TO THE PATENT LICENSING MASTER AGREEMENTPatent Licensing Master Agreement • March 2nd, 2009 • PDL Biopharma, Inc. • Biological products, (no disgnostic substances)
This Amendment No. 2 to the Patent Licensing Master Agreement (“Amendment”) is entered into as of December 18, 2003 by and between Genentech, Inc. (“GNE”), a Delaware corporation having offices at 1 DNA Way, South San Francisco, California 94080 and Protein Design Labs, Inc. (“PDL”), a Delaware corporation having offices at 34801 Campus Drive, Fremont, California 94555 (collectively, the “Parties”) and amends that certain Patent Licensing Master Agreement dated September 25, 1998 (including the form PDL License Agreement attached thereto as Exhibit C), as amended by Amendment No. 1 to the Patent Licensing Master Agreement dated September 18, 2003 (collectively the “PLMA”). Except as expressly provided herein, capitalized terms shall have the meanings set forth in the PLMA and references to Sections, Exhibits and Articles shall be deemed references to the PLMA.
CONFIDENTIAL PROVISIONS MARKEDPatent Licensing Master Agreement • March 8th, 2004 • Protein Design Labs Inc/De • Biological products, (no disgnostic substances)
This Amendment No. 2 to the Patent Licensing Master Agreement (“Amendment”) is entered into as of December 18, 2003 by and between Genentech, Inc. (“GNE”), a Delaware corporation having offices at 1 DNA Way, South San Francisco, California 94080 and Protein Design Labs, Inc. (“PDL”), a Delaware corporation having offices at 34801 Campus Drive, Fremont, California 94555 (collectively, the “Parties”) and amends that certain Patent Licensing Master Agreement dated September 25, 1998 (including the form PDL License Agreement attached thereto as Exhibit C), as amended by Amendment No. 1 to the Patent Licensing Master Agreement dated September 18, 2003 (collectively the “PLMA”). Except as expressly provided herein, capitalized terms shall have the meanings set forth in the PLMA and references to Sections, Exhibits and Articles shall be deemed references to the PLMA.
Confidential Treatment Requested PATENT LICENSING MASTER AGREEMENT This PATENT LICENSING MASTER AGREEMENT (the "Agreement") is entered into as of September 25, 1998 (the "Effective Date") by and between Protein Design Labs, Inc., a corporation...Patent Licensing Master Agreement • November 16th, 1998 • Protein Design Labs Inc/De • Biological products, (no disgnostic substances) • California
CONFIDENTIAL PROVISIONS MARKED AMENDMENT NO. 1 TO THE PATENT LICENSING MASTER AGREEMENTPatent Licensing Master Agreement • March 8th, 2004 • Protein Design Labs Inc/De • Biological products, (no disgnostic substances)
This AMENDMENT NO. 1 TO THE PATENT LICENSING MASTER AGREEMENT (the “Amendment”), is entered into as of September 18, 2003 by and between Genentech, Inc. (“GNE”), a Delaware corporation having offices at 1 DNA Way, South San Francisco, California 94080 and PROTEIN DESIGN LABS, INC., a Delaware corporation having offices at 34801 Campus Drive, Fremont, California 94555 (“PDL”) and amends that certain Patent Licensing Master Agreement dated September 25, 1998 (the “Agreement”). Except as expressly provided herein, capitalized terms shall have the meaning set forth in the Agreement.
AMENDED AND RESTATED PATENT LICENSING MASTER AGREEMENT (QUEEN PATENTS)Patent Licensing Master Agreement • November 9th, 2010 • PDL Biopharma, Inc. • Biological products, (no disgnostic substances) • California
This AMENDED AND RESTATED PATENT LICENSING MASTER AGREEMENT (this “Agreement”) is entered into as of July 27, 2009 (the “Effective Date”) by and between PDL BioPharma, Inc., a corporation organized and existing under the laws of the State of Delaware and having its principal office at 932 Southwood Boulevard, Incline Village, Nevada 89451 (hereinafter referred to as “PDL”), and Genentech, Inc., a corporation organized and existing under the laws of the State of Delaware and having its principal office at 1 DNA Way, South San Francisco, California 94080 (hereinafter referred to as “GNE”).
